James M Roberts1, Darlene L Y Dai2, Zsuzsanna Hollander2, Raymond T Ng3, Scott J Tebbutt4, Pearce G Wilcox5, Don D Sin5, Bradley S Quon6. 1. Centre for Heart Lung Innovation, University of British Columbia, St. Paul's Hospital, Canada. 2. Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada. 3. Centre for Heart Lung Innovation, University of British Columbia, St. Paul's Hospital, Canada; Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada. 4. Centre for Heart Lung Innovation, University of British Columbia, St. Paul's Hospital, Canada; Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 5. Centre for Heart Lung Innovation, University of British Columbia, St. Paul's Hospital, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 6. Centre for Heart Lung Innovation, University of British Columbia, St. Paul's Hospital, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: bradley.quon@hli.ubc.ca.
Abstract
BACKGROUND: Systemic inflammation decreases with IV antibiotics during the treatment of CF pulmonary exacerbations (PEx). We used multiple reaction monitoring mass spectrometry and immunoassays to monitor blood proteins during PEx treatment to determine if early changes could be used to predict PEx outcomes following treatment. METHODS: Blood samples from 25 PEx (22 unique adults) were collected within 24h of admission, day 5, day 10, and at IV antibiotic completion. Ninety-two blood proteins involved in host immunity and inflammation were measured. RESULTS: Levels of several blood proteins changed from admission to end of IV antibiotics, most increasing with treatment. Early changes (admission to day 5) in fibrinogen levels had the strongest correlation with overall improvement in CFRSD-CRISS and FEV1% predicted by the end of treatment. CONCLUSIONS: Several plasma proteins changed significantly with IV antibiotics. Future studies will evaluate fibrinogen as an early biomarker of PEx treatment response in CF.
BACKGROUND: Systemic inflammation decreases with IV antibiotics during the treatment of CF pulmonary exacerbations (PEx). We used multiple reaction monitoring mass spectrometry and immunoassays to monitor blood proteins during PEx treatment to determine if early changes could be used to predict PEx outcomes following treatment. METHODS: Blood samples from 25 PEx (22 unique adults) were collected within 24h of admission, day 5, day 10, and at IV antibiotic completion. Ninety-two blood proteins involved in host immunity and inflammation were measured. RESULTS: Levels of several blood proteins changed from admission to end of IV antibiotics, most increasing with treatment. Early changes (admission to day 5) in fibrinogen levels had the strongest correlation with overall improvement in CFRSD-CRISS and FEV1% predicted by the end of treatment. CONCLUSIONS: Several plasma proteins changed significantly with IV antibiotics. Future studies will evaluate fibrinogen as an early biomarker of PEx treatment response in CF.
Authors: Jordana E Hoppe; Brandie D Wagner; J Kirk Harris; Steven M Rowe; Sonya L Heltshe; Emily M DeBoer; Scott D Sagel Journal: J Cyst Fibros Date: 2022-04-16 Impact factor: 5.527
Authors: Kang Dong; Kyung-Mee Moon; Virginia Chen; Raymond Ng; Leonard J Foster; Scott J Tebbutt; Bradley S Quon Journal: Sci Rep Date: 2019-11-20 Impact factor: 4.379
Authors: Alex H Gifford; Deepika Polineni; Jianghua He; Jessica L D'Amico; Dana B Dorman; Molly A Williams; Amanda B Nymon; Akshu Balwan; Theodore Budden; Jonathan B Zuckerman Journal: Sci Rep Date: 2021-03-01 Impact factor: 4.379